Neutral lipid storage disease

From WikiMD's WELLNESSPEDIA

(Redirected from Chanarin-Dorfman disease)

Chanarin-Dorfman Syndrome smear 2009-11-13

Genetic disorder characterized by the accumulation of neutral lipids in various tissues

Neutral lipid storage disease






Symptoms Muscle weakness, hepatomegaly, cardiomyopathy


Usual onset Childhood or adulthood
Duration Lifelong


Causes Genetic mutations
Risk factors Family history
Diagnosis Genetic testing, Biopsy



Treatment Symptomatic management


Prognosis Variable
Frequency Rare



Neutral lipid storage disease (NLSD) is a rare genetic disorder characterized by the accumulation of neutral lipids in various tissues of the body. This condition can affect multiple organs, including the muscle, liver, and heart.

Classification[edit]

NLSD is classified into two main types:

  • Neutral lipid storage disease with myopathy (NLSDM), also known as Chanarin-Dorfman syndrome.
  • Neutral lipid storage disease with ichthyosis (NLSDI).

Signs and Symptoms[edit]

The symptoms of NLSD can vary widely depending on the type and severity of the disease. Common symptoms include:

Genetics[edit]

NLSD is caused by mutations in specific genes responsible for lipid metabolism. The most commonly affected genes are:

  • ABHD5 (also known as CGI-58) in NLSDI
  • PNPLA2 (also known as ATGL) in NLSDM

These mutations lead to the improper breakdown and storage of neutral lipids within cells.

Diagnosis[edit]

Diagnosis of NLSD typically involves:

  • Genetic testing to identify mutations in the ABHD5 or PNPLA2 genes.
  • Biopsy of affected tissues to observe lipid accumulation.

Treatment[edit]

There is currently no cure for NLSD. Treatment focuses on managing symptoms and may include:

  • Physical therapy for muscle weakness
  • Medications for heart and liver complications
  • Skin care for ichthyosis

Prognosis[edit]

The prognosis for individuals with NLSD varies. Some may experience mild symptoms, while others may have severe complications affecting their quality of life.

Related Pages[edit]

Categories[edit]

Stub icon

This genetic disorder article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Neutral_lipid_storage_disease&oldid=5832987"